GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.
Read the full article on the original site.
Read Full Article